Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.
Department of Pathology, Texas Tech University Health Sciences Center, El Paso, TX, USA.
Am J Clin Pathol. 2022 Apr 1;157(4):518-530. doi: 10.1093/ajcp/aqac016.
Primary myelofibrosis (PMF) is a BCR/ABL1-negative myeloproliferative neoplasm (MPN) with a shorter overall survival and a higher leukemic transformation than other BCR/ABL1-negative MPNs. Diagnosis of PMF can be challenging given its clinical, morphologic, molecular overlap with other myeloid neoplasms also associated with myelofibrosis, and reactive conditions.
We summarize and discuss the clinical, morphologic, and molecular features useful for diagnosing PMF as well as salient features helpful in distinguishing PMF from myelodysplastic syndrome with associated fibrosis and autoimmune myelofibrosis using a case-based approach.
PMF in both its prefibrotic and fibrotic stages, the latter characterized by reticulin/collagen marrow fibrosis, is characterized by a proliferation of predominantly abnormal megakaryocytes and granulocytes in the bone marrow. Driver mutations in JAK2, CALR, or MPLare seen in approximately 90% of PMF cases. In triple-negative cases, the presence of cytogenetic abnormalities and other somatic mutations identified by next-generation sequencing can help establish a diagnosis of PMF in the appropriate clinical and morphologic context.
Given the significant difference in prognosis and treatment, integration of clinical, morphological, and molecular/genetic findings is essential in distinguishing PMF from other etiologies that can demonstrate myelofibrosis.
原发性骨髓纤维化(PMF)是一种 BCR/ABL1 阴性骨髓增殖性肿瘤(MPN),其总生存期比其他 BCR/ABL1 阴性 MPN 更短,白血病转化率更高。鉴于其与其他也伴有骨髓纤维化和反应性疾病的髓系肿瘤在临床、形态学和分子学上存在重叠,PMF 的诊断具有一定挑战性。
我们采用病例为基础的方法,总结和讨论了有助于诊断 PMF 的临床、形态学和分子学特征,以及有助于将 PMF 与伴有纤维化的骨髓增生异常综合征和自身免疫性骨髓纤维化相鉴别的显著特征。
在纤维化前和纤维化阶段的 PMF 中,后者的特征是网状纤维/胶原骨髓纤维化,主要表现为骨髓中异常巨核细胞和粒细胞的增殖。约 90%的 PMF 病例存在 JAK2、CALR 或 MPL 的驱动突变。在三阴性病例中,在适当的临床和形态学背景下,通过下一代测序识别细胞遗传学异常和其他体细胞突变的存在有助于确立 PMF 的诊断。
鉴于预后和治疗存在显著差异,将临床、形态学和分子/遗传学发现相结合对于将 PMF 与其他可表现为骨髓纤维化的病因区分开来至关重要。